

PRESS RELEASE

The CardioSecur Trials Program Supports mHealth Projects

Personal MedSystems, manufacturer of CardioSecur, the only 22-lead mobile ECG solution, is promoting innovative cardiac research projects through its CardioSecur Trials program. Through this, participants receive up to 10 mobile ECG systems for their research projects. The goal of the program is to facilitate scientific research and gain insights into the effects of mHealth on cardiac patients and their care in this rapidly growing field.

Frankfurt, October 9th 2017. The mHealth sector is forecasted to rapidly grow in the next ten years, particularly in North America, Europe, and Asia¹. Patients with chronic illnesses – including ischemia, arrhythmias, or other severe cardiac events such as myocardial infarction – can greatly benefit from new mobile technologies. This is where the CardioSecur Trials program comes in: researchers who are interested in examining mobile ECG technology within the field of cardiology are supported by this program. A focus is placed on work looking at the reduction of disease burden and / or improving patient diagnosis or therapy via mobile ECG diagnostics.

With CardioSecur Active, Personal MedSystems offers mobile technology which patients can use anytime and anywhere to record an ECG using only their own smartphone and four electrodes, most importantly when symptoms are present. The patient receives immediate feedback in one of three levels (neutral, yellow, or red) regarding the reading, and their doctor can receive comprehensive data from the moment symptoms occur—this can be critical information for establishing a diagnosis and treatment. CardioSecur Pro is based upon the same technology, but is designed for use by physicians. It provides the benefits of being mobile, intuitive, cost-effective, and most importantly, comprehensive. Both products are available through the CardioSecur Trials program.

Interested persons in participating in a CardioSecur Trials project, are can get in touch with Personal MedSystems in order to discuss possible project ideas.

More information available at <https://www.mobile-ecg.com/>

Personal MedSystems GmbH develops and sells ECG systems and services for private users and healthcare professionals under the name CardioSecur. **CardioSecur Active** is an innovative, 15-lead, clinical-grade ECG for personal use. In a few seconds, it generates personalized feedback regarding changes in the heart's health and provides a simple recommendation to act regarding whether to see a doctor or not. The entire system consists of a 50g light cable with four electrodes, the complimentary CardioSecur Active App and the user's smartphone or tablet. **CardioSecur Pro** is the mobile, clinical ECG solution for physicians and medical professionals. CardioSecur Pro operates based upon guidelines from the European Society of Cardiology by providing 22 leads, making a 360° view of the heart possible. It is the only system that thereby recognizes infarctions of the anterior, lateral and posterior walls of the heart.

CardioSecur Trials Contact:

Personal MedSystems GmbH

Jessica Thür

Telephone +49 (0) 69 907 2013 0

thuer@cardiosecur.com

Press Contact:

Personal MedSystems GmbH

Susanne Brückner

Telephone +49 (0) 171-3538012

brueckner@cardiosecur.com

¹mHealth Services Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014-2020